AUREALIS THERAPEUTICS

They exist to develop curative solutions that achieve total and faster healing for non-healing wounds and other complex inflammatory diseases with their four-in-one biologic drug, AUP-16. Their goal is to create solid Phase 2 clinical efficacy data in diabetic foot ulcers and non-clinical proof-of-concept data in other inflammatory diseases by end of 2022, and to engage with strategic partners to ensure that this game changing technology benefits millions of patients.